BRAF and KRAS

Data Source:
BioGRID (fluorescent resonance energy transfer, affinity chromatography technology)

		BRAF	KRAS
Description		B-Raf proto-oncogene, serine/threonine kinase	KRAS proto-oncogene, GTPase
Image
GO Annotations	Cellular Component	Nucleus Cytosol Plasma Membrane Intracellular Membrane-bounded Organelle	Cytoplasm Mitochondrion Cytosol Plasma Membrane Focal Adhesion Membrane Extrinsic Component Of Cytoplasmic Side Of Plasma Membrane Membrane Raft
	Molecular Function	Protein Kinase Activity Protein Serine/threonine Kinase Activity Calcium Ion Binding Protein Binding ATP Binding Small GTPase Binding Identical Protein Binding Scaffold Protein Binding Protein Serine Kinase Activity Protein Threonine Kinase Activity	GTPase Activity Protein Binding GTP Binding GMP Binding GDP Binding LRR Domain Binding Protein-containing Complex Binding
	Biological Process	MAPK Cascade Activation Of MAPKK Activity Protein Phosphorylation Epidermal Growth Factor Receptor Signaling Pathway Animal Organ Morphogenesis Positive Regulation Of Gene Expression Positive Regulation Of Glucose Transmembrane Transport Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of ERK1 And ERK2 Cascade Trehalose Metabolism In Response To Stress Cellular Response To Calcium Ion Establishment Of Protein Localization To Membrane	MAPK Cascade Liver Development Positive Regulation Of Protein Phosphorylation Stimulatory C-type Lectin Receptor Signaling Pathway Ras Protein Signal Transduction Female Pregnancy Positive Regulation Of Cell Population Proliferation Visual Learning Positive Regulation Of Gene Expression Cytokine-mediated Signaling Pathway Forebrain Astrocyte Development Actin Cytoskeleton Organization Regulation Of Protein Stability Regulation Of Synaptic Transmission, GABAergic Positive Regulation Of Rac Protein Signal Transduction Response To Isolation Stress Endocrine Signaling Positive Regulation Of MAP Kinase Activity Negative Regulation Of Neuron Apoptotic Process Negative Regulation Of Cell Differentiation Regulation Of Long-term Neuronal Synaptic Plasticity Homeostasis Of Number Of Cells Within A Tissue Positive Regulation Of Nitric-oxide Synthase Activity Positive Regulation Of NF-kappaB Transcription Factor Activity Striated Muscle Cell Differentiation Response To Glucocorticoid Response To Mineralocorticoid Epithelial Tube Branching Involved In Lung Morphogenesis Positive Regulation Of Cellular Senescence
Pathways		Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants	Signaling by moderate kinase activity BRAF mutants Paradoxical activation of RAF signaling by kinase inactive BRAF RUNX3 regulates p14-ARF RAS processing RAS GTPase cycle mutants Signaling downstream of RAS mutants
Drugs		Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib	[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID Farnesyl diphosphate MRTX849 AMG-510
Diseases		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma	Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Pancreatic cancer Gastric cancer Colorectal cancer Non-small cell lung cancer Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Oral cancer Acute myeloid leukemia (AML) Endometrial Cancer Multiple myeloma Squamous cell carcinoma Kaposi's sarcoma Cholangiocarcinoma Thyroid cancer Cervical cancer Hepatocellular carcinoma Ovarian cancer Gallbladder cancer
GWAS		anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Bipolar disorder ( 31043756) Cerebrospinal fluid t-tau:AB1-42 ratio ( 26252872) Cerebrospinal T-tau levels ( 26252872) Mild influenza (H1N1) infection ( 26379185) Response to Vitamin E supplementation ( 22437554) Type 2 diabetes ( 32499647 28869590)	Disease progression in age-related macular degeneration (adjusted for baseline) ( 29346644) Dysmenorrheic pain ( 27454463)
Interacting Genes		46 interacting genes: AKT1 ARAF AURKA BAD CCDC88A CTSV FBP1 HRAS HSD17B3 ITCH KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAPK1 MAPK3 MRAS NANOG OIP5 PAK2 PEBP1 PPP2CA PPP2R2A PRKACA PRKCE RAF1 RAP1A RAP1GAP RASSF1 RHEB SFN SGK1 SPRY2 STK11 TERF1 TERT UBE2L3 YWHAB YWHAG YWHAH YWHAQ YWHAZ ZNF189 ZNF510	63 interacting genes: ADH6 ARAF ARL6IP5 BCAS3 BCL2 BRAF CALM1 CCL5 CCT7 CDK8 DDX47 DDX50 DIRAS3 DNAJA3 EGLN1 EPB42 FANCC FNTA FNTB FRAT2 HEMGN HNRNPC HRAS IGFBP3 IGSF21 IL24 LPAR1 LYPD4 LZTR1 MDFI MOCS2 MT-CO3 MT-CYB NDUFA13 OSGIN1 PDE4DIP PGGT1B PIK3CA PIK3CG PIK3R2 PIP5K1A PPP2CB PSMA3 QDPR RAF1 RALGDS RAP1GDS1 RASGRF2 RASGRP2 RASSF2 RASSF5 RBPMS RGL2 SERPINB5 SHOC2 SOX4 STX17 THRSP TNFSF13 UQCRC1 WDR76 ZDHHC17 ZNF189
Entrez ID		673	3845
HPRD ID		01264	01817
Ensembl ID		ENSG00000157764	ENSG00000133703
Uniprot IDs		P15056	A0A024RAV5 I1SRC5 L7RSL8 P01116
PDB IDs		1UWH 1UWJ 2FB8 2L05 3C4C 3D4Q 3IDP 3II5 3NY5 3OG7 3PPJ 3PPK 3PRF 3PRI 3PSB 3PSD 3Q4C 3Q96 3SKC 3TV4 3TV6 4CQE 4DBN 4E26 4E4X 4EHE 4EHG 4FC0 4FK3 4G9C 4G9R 4H58 4JVG 4KSP 4KSQ 4MBJ 4MNE 4MNF 4PP7 4R5Y 4RZV 4RZW 4WO5 4XV1 4XV2 4XV3 4XV9 4YHT 5C9C 5CSW 5CSX 5CT7 5FD2 5HI2 5HID 5HIE 5ITA 5J17 5J18 5J2R 5JRQ 5JSM 5JT2 5VAL 5VAM 5VR3 5VYK 6B8U 6CAD 6N0P 6N0Q 6NSQ 6NYB 6P3D 6P7G 6PP9 6Q0J 6Q0K 6Q0T 6U2G 6U2H 6UAN 6UUO 6XAG	1D8D 1D8E 1KZO 1KZP 1N4P 1N4Q 1N4R 1N4S 2MSC 2MSD 2MSE 3GFT 4DSN 4DSO 4EPR 4EPT 4EPV 4EPW 4EPX 4EPY 4L8G 4LDJ 4LPK 4LRW 4LUC 4LV6 4LYF 4LYH 4LYJ 4M1O 4M1S 4M1T 4M1W 4M1Y 4M21 4M22 4NMM 4OBE 4PZY 4PZZ 4Q01 4Q02 4Q03 4QL3 4TQ9 4TQA 4WA7 5F2E 5KYK 5MLA 5MLB 5O2S 5O2T 5OCG 5OCO 5OCT 5TAR 5TB5 5UFE 5UFQ 5UK9 5UQW 5US4 5USJ 5V6S 5V6V 5V71 5V9L 5V9O 5V9U 5VBM 5VP7 5VPI 5VPY 5VPZ 5VQ0 5VQ1 5VQ2 5VQ6 5VQ8 5W22 5WHA 5WHB 5WHD 5WHE 5WLB 5WPM 5XCO 5YXZ 5YY1 6ARK 6ASA 6ASE 6B0V 6B0Y 6BOF 6BP1 6CC9 6CCH 6CCX 6CU6 6E6F 6E6G 6EPL 6EPM 6EPN 6EPO 6EPP 6F76 6FA1 6FA2 6FA3 6FA4 6GJ5 6GJ6 6GJ7 6GJ8 6GOD 6GOE 6GOF 6GOG 6GOM 6GQT 6GQW 6GQX 6GQY 6H46 6H47 6JTN 6JTO 6JTP 6M9W 6MBQ 6MBT 6MBU 6MNX 6MQG 6MQN 6MS9 6MTA 6N2J 6N2K 6O36 6O46 6O4Y 6O4Z 6O51 6O53 6OB2 6OB3 6OIM 6P0Z 6P8W 6P8X 6P8Y 6P8Z 6PGO 6PGP 6PQ3 6PTS 6PTW 6QUU 6QUV 6QUW 6QUX 6T5B 6T5U 6T5V 6TAM 6TAN 6USX 6USZ 6UT0 6V5L 6V65 6V6F 6W4E 6W4F 6WGN 6YR8 6YXW 6ZL5 6ZLI
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?